Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $16.50.

A number of brokerages recently issued reports on NMRA. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Neumora Therapeutics in a report on Thursday, January 2nd. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $18.00 to $15.00 in a report on Tuesday, November 5th. Bank of America cut their price target on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Neumora Therapeutics in a report on Friday, January 3rd. Finally, William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th.

Neumora Therapeutics Stock Up 0.5 %

NASDAQ:NMRA opened at $1.93 on Monday. Neumora Therapeutics has a 52 week low of $1.83 and a 52 week high of $21.00. The business’s 50-day simple moving average is $6.77 and its two-hundred day simple moving average is $10.39. The stock has a market cap of $311.81 million, a PE ratio of -1.03 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the prior year, the company earned ($1.14) earnings per share. Sell-side analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Several institutional investors have recently modified their holdings of the company. Amalgamated Bank raised its stake in Neumora Therapeutics by 472.8% during the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after acquiring an additional 2,402 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Neumora Therapeutics during the 4th quarter worth $61,000. Quarry LP acquired a new position in Neumora Therapeutics in the second quarter valued at $98,000. Intech Investment Management LLC acquired a new position in Neumora Therapeutics in the third quarter valued at $175,000. Finally, Ballentine Partners LLC acquired a new position in Neumora Therapeutics in the third quarter valued at $178,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.